Status:
COMPLETED
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
Lead Sponsor:
Pfizer
Conditions:
Pancreatitis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g IV meropenem given during the induction period o...
Eligibility Criteria
Inclusion
- Subjects with diagnosis of severe pancreatitis requiring surgery according to the protocol of each Institution.
- Informed consent signed by the subject
- Subjects who have received prophylactic antibiotics for previous invasive procedures different from surgery may be included
Exclusion
- Will of the subject not to be included
- Subjects who have not signed the informed consent
- Subjects with known hypersensibility to carbapenems, penicillins, or cephalosporins
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00318994
Start Date
February 1 2002
End Date
May 1 2007
Last Update
September 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bogotá, Colombia